Robert Bucki1, Dorota B Namiot, Zbigniew Namiot, Paul B Savage, Paul A Janmey. 1. Department of Physiology, Institute for Medicine and Engineering, University of Pennsylvania, 1010 Vagelos Research Laboratories, 3340 Smith Walk, Philadelphia, PA 19104, USA. buckirob@mail.med.upenn.edu
Abstract
OBJECTIVES: Cationic antimicrobial peptides (CAPs) are the effector molecules of innate immunity, similar in potency to classic antibiotics that function in the first-line of defence against infectious agents. The purpose of this study was to investigate the effects of negatively charged mucins on the antibacterial activity of the positively charged cathelicidin LL-37 peptide, its synthetic analogue WLBU2 and the antimicrobial cationic steroid CSA-13. METHODS: Mucin, DNA, F-actin and hCAP-18/LL-37 in saliva samples were evaluated by microscopy or immunoblotting. Bacterial killing assays and determination of MICs were used to determine bactericidal activity. Binding of rhodamine-B-labelled LL-37 peptide to mucin was fluorimetrically assessed. RESULTS: Microscopic evaluation of saliva after addition of rhodamine-B-labelled LL-37 showed localization similar to that observed after the addition of a specific mucin-binding lectin. Immunoblotting confirmed the presence of hCAP-18/LL-37 in saliva samples and LL-37 peptide bound to isolated submaxillary gland mucin-coated plates. Mucin/LL-37 binding was partially prevented by treatment of mucin with neuraminidase, indicating involvement of sialic acid moieties. Decreased LL-37 and WLBU2 antibacterial activity was observed in the presence of mucin or dialysed human saliva, whereas CSA-13 antibacterial activity was significantly resistant to inhibition by mucins. CONCLUSIONS: This study shows that the antibacterial LL-37 peptide and its synthetic analogue WLBU2 are inhibited by salivary mucin and that the cationic steroid CSA-13 retains most of its function in the presence of an equal amount of mucin or saliva.
OBJECTIVES: Cationic antimicrobial peptides (CAPs) are the effector molecules of innate immunity, similar in potency to classic antibiotics that function in the first-line of defence against infectious agents. The purpose of this study was to investigate the effects of negatively charged mucins on the antibacterial activity of the positively charged cathelicidin LL-37 peptide, its synthetic analogue WLBU2 and the antimicrobial cationic steroidCSA-13. METHODS:Mucin, DNA, F-actin and hCAP-18/LL-37 in saliva samples were evaluated by microscopy or immunoblotting. Bacterial killing assays and determination of MICs were used to determine bactericidal activity. Binding of rhodamine-B-labelled LL-37 peptide to mucin was fluorimetrically assessed. RESULTS: Microscopic evaluation of saliva after addition of rhodamine-B-labelled LL-37 showed localization similar to that observed after the addition of a specific mucin-binding lectin. Immunoblotting confirmed the presence of hCAP-18/LL-37 in saliva samples and LL-37 peptide bound to isolated submaxillary gland mucin-coated plates. Mucin/LL-37 binding was partially prevented by treatment of mucin with neuraminidase, indicating involvement of sialic acid moieties. Decreased LL-37 and WLBU2 antibacterial activity was observed in the presence of mucin or dialysed human saliva, whereas CSA-13 antibacterial activity was significantly resistant to inhibition by mucins. CONCLUSIONS: This study shows that the antibacterial LL-37 peptide and its synthetic analogue WLBU2 are inhibited by salivary mucin and that the cationic steroidCSA-13 retains most of its function in the presence of an equal amount of mucin or saliva.
Authors: Martin Malmsten; Mina Davoudi; Björn Walse; Victoria Rydengård; Mukesh Pasupuleti; Matthias Mörgelin; Artur Schmidtchen Journal: Growth Factors Date: 2007-02 Impact factor: 2.511
Authors: O E Sørensen; P Follin; A H Johnsen; J Calafat; G S Tjabringa; P S Hiemstra; N Borregaard Journal: Blood Date: 2001-06-15 Impact factor: 22.113
Authors: Rembert Koczulla; Georges von Degenfeld; Christian Kupatt; Florian Krötz; Stefan Zahler; Torsten Gloe; Katja Issbrücker; Pia Unterberger; Mohamed Zaiou; Corinna Lebherz; Alexander Karl; Philip Raake; Achim Pfosser; Peter Boekstegers; Ulrich Welsch; Pieter S Hiemstra; Claus Vogelmeier; Richard L Gallo; Matthias Clauss; Robert Bals Journal: J Clin Invest Date: 2003-06 Impact factor: 14.808
Authors: Markus O Henke; Armin Renner; Rudolf M Huber; Michael C Seeds; Bruce K Rubin Journal: Am J Respir Cell Mol Biol Date: 2004-02-26 Impact factor: 6.914
Authors: K D Sinclair; T X Pham; R W Farnsworth; D L Williams; C Loc-Carrillo; L A Horne; S H Ingebretsen; R D Bloebaum Journal: J Biomed Mater Res A Date: 2012-05-24 Impact factor: 4.396
Authors: K Leszczyńska; A Namiot; K Cruz; F J Byfield; E Won; G Mendez; W Sokołowski; P B Savage; R Bucki; P A Janmey Journal: J Appl Microbiol Date: 2010-10-21 Impact factor: 3.772
Authors: Kiran S Ambatipudi; Fred K Hagen; Claire M Delahunty; Xuemei Han; Rubina Shafi; Jennifer Hryhorenko; Stacy Gregoire; Robert E Marquis; James E Melvin; Hyun Koo; John R Yates Journal: J Proteome Res Date: 2010-10-22 Impact factor: 4.466
Authors: Robert Bucki; Katarzyna Niemirowicz; Urszula Wnorowska; Fitzroy J Byfield; Ewelina Piktel; Marzena Wątek; Paul A Janmey; Paul B Savage Journal: Antimicrob Agents Chemother Date: 2015-07-27 Impact factor: 5.191
Authors: Katarzyna Leszczyńska; Andrzej Namiot; David E Fein; Qi Wen; Zbigniew Namiot; Paul B Savage; Scott Diamond; Paul A Janmey; Robert Bucki Journal: BMC Microbiol Date: 2009-09-03 Impact factor: 3.605